// App-Quantinova.ai

TPS9639 : Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting for gynecological cancer: KCOG G-1301 phase II trial.

Researchers

Presenter

  • Masakazu Abe

Principal Investigators

  • Yuka Kasamatsu

  • Kado Nobuhiro

  • Yui Itonaga

  • Tomoko Hirakawa

  • Kaei Nasu

  • Kanoko Miyagi

  • Junko Murakami

  • Nobutaka Takahashi

  • Munetaka Takekuma

  • Yasuyuki Hirashima

  • Shin Nishio

  • Yoshio Itani

  • Yoshikazu Ichikawa

  • Kimihiko Ito

  • Shiho Kuji

  • Aki Tanaka

Medical Centers

  • Department of Gynecologic Oncology, Shizuoka Cancer Center, Shizuoka, Japan

  • Kurume University School of Medicine, Kurume-shi, JapanNara Prefectural Nara Hospital, Nara, JapanShizuoka Red Cross Hospital, Shizuoka, Japan

  • Department of Obstetrics and Gynecology, Faculty of Medicine, Kagoshima University, Kagoshima, Japan

  • Department of Obstetrics and Gynecology, Kansai Rosai Hospital, Hyogo, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chemotherapy-induced nausea and vomiting

  • Gynaecological cancer

  • Diabetes

  • Solid malignancies

Biomarkers

  • NDC80 Kinetochore Complex Component

  • Hemoglobin A1c

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Palonosetron

  • Aprepitant

  • Olanzapine

  • Cisplatin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • UMIN000011857

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved